Skip to content

A Study on the Clinical Application of HFNC during the Perioperative Period of Gastric Reduction Surgery

A Study on the Clinical Application of HFNC during the Perioperative Period of Gastric Reduction Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125809
Enrollment
Unknown
Registered
2026-06-01
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

HFNC oxygen group:Oxygen is delivered via high-flow nasal cannula (HFNC). The oxygen concentration is set to 100%, humidity to 100%, and temperature to 37 °C. After the initiation of anesthesia induct
Mask oxygen group:Oxygen is delivered via a conventional face mask at a routine flow rate of 6 L/min and 100% oxygen concentration. The duration of preoxygenation is no less than 3 minutes.

Sponsors

The Second Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Age: 18–70 years 2.Obese patients undergoing elective gastric reduction surgery 3.No contraindications to HFNC or mask oxygen therapy 4.BMI >= 32.5 kg/m^2 5.ASA Class I–III 6.No severe cardiopulmonary failure, airway obstruction or other critical illnesses 7.Agree to participate in the study and sign the informed consent

Exclusion criteria

Exclusion criteria: 1.Age 70 years 2.ASA Class IV or higher 3.BMI 55 kg/m^2 4.Severe cardiovascular diseases (ischemic heart disease, heart failure, severe angina, unstable angina or myocardial infarction within 6 months); severe hypertension (SBP > 180 mmHg, DBP > 110 mmHg); hypotension (SBP < 90 mmHg) 5.Severe respiratory diseases (COPD, respiratory failure, asthma, pulmonary bullae, recent upper respiratory tract infection, prior thoracic surgery); hypoxemia (SpO2 < 92%) 6.Severe hepatic and renal disorders 7.Intraoperative change of surgical plan or severe intraoperative complications affecting respiratory function assessment 8.Allergy to active components of sufentanil, remifentanil, propofol injection or medical dressings 9.Contraindications to HFNC, e.g. severe nasal deformity, massive nasal bleeding 10.Failure to cooperate with assessments and follow-up; incomplete data unavailable for machine learning modeling

Design outcomes

Primary

MeasureTime frame
Incidence of hypoxemia;

Secondary

MeasureTime frame
Baseline characteristics;Preoperative Preoxygenation Assessment;Frequency of intraoperative interventions for SpO2 = 92%;Post-anesthesia Recovery Assessment;Pulmonary complications;Anesthesia time;Surgery time;Extubation time;PACU length of stay;Incidence of unplanned ICU admission;Incidence of unplanned re-intubation;Length of hospital stay;Anesthesia cost;Total hospital cost;

Countries

China

Contacts

Public ContactPeng Pan

The Second Affiliated Hospital of Harbin Medical University

panpeng1982@163.com+86 86605452

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026